Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1161/01.ATV.20.1.189PMID 10634817
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects

  2004cited by this paper
• [HMG-CoA reductase inhibitors].

  1998cited by this paper
• Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.

  1998cited by this paper
• A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.

  1998cited by this paper
• Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction.

  1998cited by this paper
• Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells.

  1998cited by this paper
• Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits.

  1998cited by this paper
• Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

  1998cited by this paper
• Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.

  1997cited by this paper
• A brief review paper of the efficacy and safety of atorvastatin in early clinical trials.

  1997cited by this paper
• Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.

  1997cited by this paper
• Lipoprotein heterogeneity and apolipoprotein B metabolism.

  1997cited by this paper
• Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.

  1997cited by this paper
• A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

  1997cited by this paper
• Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.

  1997cited by this paper
• A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.

  1997cited by this paper
• Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

  1996cited by this paper
• Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.

  1996cited by this paper
• Human Cholesteryl Ester Transfer Protein Gene Proximal Promoter Contains Dietary Cholesterol Positive Responsive Elements and Mediates Expression in Small Intestine and Periphery While Predominant Liver and Spleen Expression Is Controlled by 5′-distal Sequences

  1996cited by this paper
• Absence of cholesteryl ester transfer protein‐mediated cholesteryl ester mass transfer from high‐density lipoprotein to low‐density lipoprotein particles is a major feature of combined hyperlipidaemia

  1996cited by this paper
• Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia.

  1995cited by this paper
• Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.

  1995cited by this paper
• A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma.

  1994cited by this paper
• Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies.

  1994cited by this paper
• [Effects of an educational campaign on cardiovascular risk factors in a French town (Epernon, study town). Methods and preliminary results: prevalence and level of risk factors].

  1994cited by this paper
• Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk.

  1994cited by this paper
• McCollum Award Lecture, 1993: triglyceride-rich lipoproteins and atherosclerosis--new perspectives.

  1994cited by this paper
• Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects.

  1993cited by this paper
• Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.

  1993cited by this paper
• Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences.

  1992cited by this paper
• Changes in particle size of high density lipoproteins during incubation with very low density lipoproteins, cholesteryl ester transfer protein and lipoprotein lipase.

  1992cited by this paper
• Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables.

  1991cited by this paper
• Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor.

  1991cited by this paper
• Role of fibric acids in the management of hyperlipidemia

  1990cited by this paper
• Lipid lowering drugs.

  1990cited by this paper
• Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.

  1990cited by this paper
• Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

  1989cited by this paper
• Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation.

  1988cited by this paper
• Characterization of human high-density lipoproteins by gradient gel electrophoresis.

  1981cited by this paper
• A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum.

  1981cited by this paper
• The Mechanism of Action of Clofibrate and Tetranicotinoylfructose (Bradilan) on the Kinetics of Plasma Free Fatty Acid and Triglyceride Transport in Type IV und Type V Hypertriglyceridaemia

  1974cited by this paper
• The Mechanism of Action of Clofibrate and Tetranicotinoylfructose (Bradilan) on the Kinetics of Plasma Free Fatty Acid and Triglyceride Transport in Type IV und Type V Hypertriglyceridaemia

  1974cited by this paper

• High-density lipoprotein: a biomarker and therapeutic target in sepsis

  2025cites this paper
• High Apolipoprotein B Levels are Associated with an Increased Risk of Recurrent Acute Ischemic Stroke: A Nested Case–Control Study

  2025cites this paper
• Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With Caution.

  2025cites this paper
• Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know.

  2025cites this paper
• Delayed atorvastatin delivery promotes recovery after experimental spinal cord injury

  2025cites this paper
• Reduced Capacity of High‐Density Lipoprotein to Acquire Free Cholesterol From Triglyceride‐Rich Lipoproteins Is Associated With Elevated Postprandial Hypertriglyceridemia in Healthy Men

  2024cites this paper
• Effect of statins in cardiovascular diseases: a prospective observational study

  2024cites this paper
• High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review

  2024cites this paper
• Pitavastatin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia

  2023influential citation
• An android app “Apolipoprotein B Calculator” calculates Apolipoprotein B using regression analysis and neural network – Using the friedewald equation is the same as directly measured low-density lipoprotein cholesterol and better at low-density lipoprotein levels

  2023cites this paper
• Review of Laboratory Methods to Determine HDL and LDL Subclasses and Their Clinical Importance

  2022cites this paper
• The Lipid Energy Model: Reimagining Lipoprotein Function in the Context of Carbohydrate-Restricted Diets

  2022cites this paper
• The association between impairment of HDL cholesterol efflux capacity and atrial remodeling in atrial fibrillation

  2021cites this paper
• Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin

  2021cites this paper
• PGPM_A_278671 1..13

  2021cites this paper
• Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

  2021cites this paper
• Reduced Reverse Cholesterol Transport Efficacy in Healthy Men with Undesirable Postprandial Triglyceride Response

  2020cites this paper
• Comparative Study of Efficacy and Safety of Atorvastatin plus Fenofibrate versus Atorvastatin plus Saroglitazar in Patients of Type 2 Diabetes Mellitus with Dyslipidemia

  2020cites this paper
• LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL[S]

  2020cites this paper
• Small dense low-density lipoprotein-lowering agents

  2019cites this paper
• Antiatherogenic properties of high-density lipoproteins from arterial plasma are attenuated as compared to their counterparts of venous origin.

  2019cites this paper
• Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.

  2018cites this paper
• Comparative Study of Atorvastatin and Rosuvastatin on Serum Lipid Profile in Cardiac Patients with Diabetes

  2018cites this paper
• Plasma lipid transfer proteins: The role of PLTP and CETP in atherogenesis.

  2018cites this paper
• A COMPARATIVE STUDY ON ATORVASTATIN ALONE VERSUS ATORVASTATIN PLUS FENOFIBRATE FOR ITS SAFETY AND EFFECTIVENESS IN HYPERLIPIDEMIC PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL

  2017cites this paper
• Early Prediction of Premature Atherosclerosis in Children with End Stage Renal Disease(ESRD) on Regular Haemodialysis, A Single Centre Experience

  2017cites this paper
• Microbiological and Histopathological studies on cholesterol reducing effect of lactobacillus acidophilus

  2017influential citation
• Indicators of Vascular Dysfunctions in Children with End Stage Renal Disease under Regular Haemodialysis as Paediatric Emergency

  2017influential citation
• Effect of dietary n-3 fatty acids supplementation on fatty acid metabolism in atorvastatin-administered SHR.Cg-Leprcp/NDmcr rats, a metabolic syndrome model.

  2017cites this paper
• The Impact of Ethnicity on Lipoproteins in Coronary Artery Disease

  2017cites this paper
• Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome.

  2017cites this paper
• Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]).

  2016cites this paper
• Lifestyle modification interventions differing in intensity and dietary stringency improve insulin resistance through changes in lipoprotein profiles

  2016cites this paper
• Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus.

  2016cites this paper
• Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

  2016cites this paper
• Basal and insulin-regulated VLDL1 and VLDL2 kinetics in men with type 2 diabetes

  2016cites this paper
• Mining genomic variants and causal pathways linking HDL and triglycerides to coronary disease

  2016cites this paper
• Comparative Study of Atorvastatin and Rosuvastatin in Combination with Fenofibrate in mixed Hyperlipidemia

  2016cites this paper
• Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia

  2016cites this paper
• Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function.

  2015cites this paper
• High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk

  2015cites this paper
• Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART[S]

  2015cites this paper
• Índice tobillo-brazo en la identificación de aterogénesis subclínica en pacientes con insuficiencia hepática crónica

  2015cites this paper
• Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin.

  2015cites this paper
• Lipid-lowering efficacy of atorvastatin.

  2015cites this paper
• Comparative Study of Atorvastatin plus Fenofibrate versus Atorvastatin alone for its safety and efficacy in Hyperlipidemic patients

  2015influential citation
• Lipids in health and disease

  2014cites this paper
• Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.

  2014cites this paper
• Effects of Omega-3 on Lipid Profile and Haematological Parameters in Hyperlipidemic Rats

  2014cites this paper
• Role of Magnesium Supplement on Hyperlipidemia and L-CAT Level in Patient on Atorvastatin Therapy

  2014cites this paper
• Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels

  2014cites this paper
• Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathy

  2014cites this paper
• Chemical modification of high density lipoprotein subfractions - HDL2 and HDL3 - after use of atorvastatin.

  2014cites this paper
• Resistin , an Adipokine , Its Relation to Inflammation in Systemic Lupus Erythematosus and Rheumatoid Arthritis

  2014cites this paper
• EFFECTS OF LIPOPHILIC STATIN ON GLUCOSE INDICES IN OBESE HYPERLIPIDEMIC PATIENTS WITH TYPE 2 DIABETES

  2013cites this paper
• Clinical and Biological Relevance of Statin-Mediated Changes in HDL Metabolism

  2013cites this paper
• A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia

  2013cites this paper
• Effects of atorvastatin and T-786C polymorphism of eNOS gene on plasma metabolic lipid parameters.

  2013cites this paper
• Unraveling the complexities of the HDL lipidome1

  2013cites this paper
• Humoral response towards high density lipoprotein : a new mechanism for atherogenesis

  2013cites this paper
• Glycemic control and high‐density lipoprotein characteristics in adolescents with type 1 diabetes

  2013cites this paper
• Dysfunctional HDL-cholesterol: a potential link between high levels of HDL-cholesterol and cardiovascular disease?

  2013cites this paper
• Effects of pitavastatin on HDL metabolism

  2013cites this paper
• Implication des phagocytes mononucléés dans les pathologies inflammatoires chroniques : exploration d’un modèle murin d’athérosclérose et du xanthogranulome chez l’homme

  2012cites this paper
• Lipids, Atherogenic Dyslipidemia, and Therapy

  2012cites this paper
• Estudio de las subfracciones lipoproteicas tras el tratamiento de simvastatina y ezetimiba, en monoterapia o combinado, en pacientes hiperlipidémicos

  2012cites this paper
• Low High-Density Lipoprotein Cholesterol

  2012cites this paper
• Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia

  2012cites this paper
• Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?

  2012cites this paper
• Lipidomics in Lipoprotein Biology

  2012cites this paper
• Lipid lowering efficacy of atorvastatin.

  2012cites this paper
• Reverse cholesterol transport in familial hypercholesterolemia

  2012cites this paper
• Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitus.

  2012cites this paper
• Switching to Pitavastatin in Statin-Treated Low HDL-C Patients Further Improves the Lipid Profile and Attenuates Minute Myocardial Damage

  2012cites this paper
• Abnormal High-Density Lipoproteins in Overweight Adolescents With Atherogenic Dyslipidemia

  2011cites this paper
• "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.

  2011cites this paper
• Enhancement of HDL Formation and Normalization of Intravascular HDL Remodeling

  2011cites this paper
• Improved in vitro dissolution parameters and in vivo hypolipidemic efficiency of atorvastatin calcium through the formation of hydrophilic inclusion complex with cyclodextrins

  2011influential citation
• Statins in the Reduction of Cardiovascular Events

  2011cites this paper
• Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes.

  2011cites this paper
• Rosuvastatin does not affect human apolipoprotein A‐I expression in genetically modified mice: a clue to the disputed effect of statins on HDL

  2011cites this paper
• Lipid profiling of lipoproteins by electrospray ionization tandem mass spectrometry.

  2011cites this paper
• Ezetimibe and reactive oxygen species.

  2011cites this paper
• Atheroprotective Reverse Cholesterol Transport Pathway Is Defective in Familial Hypercholesterolemia

  2011cites this paper
• Effect of bariatric surgery-induced weight loss on SR-BI-, ABCG1-, and ABCA1-mediated cellular cholesterol efflux in obese women.

  2011cites this paper
• Estimation of the low-density lipoprotein (LDL) subclass phenotype using a direct, automated assay of small dense LDL-cholesterol without sample pretreatment.

  2010cites this paper
• Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes

  2010cites this paper
• Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

  2010cites this paper
• Effects of Statins on HDL Metabolism

  2010cites this paper
• High-density lipoprotein-raising strategies: update 2010.

  2010cites this paper
• No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin

  2010cites this paper
• High Density Lipoprotein Particles

  2010cites this paper
• Comparative laboratory study on the effects of certain types of lipids on the concentration of plasma total cholesterol (TC) and high density lipoprotein (HDL-C) in hamster.

  2010cites this paper
• High-density lipoprotein and coronary heart disease: current and future therapies.

  2010cites this paper
• Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia.

  2010cites this paper
• Atorvastatin Reduces Plaque Vulnerability in an Atherosclerotic Rabbit Model by Altering the 5-Lipoxygenase Pathway

  2010cites this paper
• EGYETEMI DOKTORI (Ph.D.) ÉRTEKEZÉS Az atorvastatin kezelés és az uncoupling protein-2 hatása és szerepe a zsíranyagcserében

  2010cites this paper
• The puzzle of high-density lipoprotein in cardiovascular prevention

  2009cites this paper
• Benefits and Difficulties in Measuring HDL Subfractions and Human Paraoxonase-1 Activity During Statin Treatment

  2009cites this paper
• Atherogenic lipid phenotype in a general group of subjects.

  2009cites this paper